Also trades as: BIAF (NASDAQ) · $vol 15M
BIAFW NASDAQ
bioAffinity Technologies, Inc.
1W: -7.2%
1M: -25.4%
3M: -0.1%
YTD: -14.3%
1Y: -69.4%
$0.22
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.0M
52W Range0.2201-0.47
Volume271
Avg Volume2,172
Beta-1.19
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMaria Zannes
Employees57
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2022-09-01
Websitebioaffinitytech.com
3300 Nacogdoches Road
San Antonio, DE
US
San Antonio, DE
US
+1 210 698 5334
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
Latest News
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 1.1% – Time to Sell?
bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 142.0% in March
bioAffinity Technologies (NASDAQ:BIAFW) Shares Down 15.3% – Time to Sell?
bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 164.9% in February
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 10.8% – Here’s What Happened
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rios Roberto | 0 | — | 2025-08-12 | |
| Oppenheimer John J. | 0 | — | 2025-08-12 | |
| Reveles Xavier Trini | A-Award | 21,604 | — | 2025-01-10 |
| GIRGENTI STEVEN | A-Award | 14,814 | — | 2025-01-10 |
| Zannes Maria | A-Award | 37,037 | — | 2025-01-10 |